How Much Does Wegovy Cost? (2026 Pricing Guide)

Wegovy List Price Breakdown

Wegovy (semaglutide 2.4mg injection) is manufactured by Novo Nordisk and is the only FDA-approved semaglutide specifically indicated for chronic weight management. Unlike Ozempic, which is approved for type 2 diabetes and used off-label for weight loss, Wegovy carries a dedicated obesity indication.

The wholesale acquisition cost (WAC) for Wegovy is approximately $1,349 per month across all dose levels. This is the price pharmacies pay before any negotiated rebates, and it is the price most uninsured patients will encounter at the retail counter.

• Wegovy 0.25mg (starting dose): $1,349/month
• Wegovy 0.5mg: $1,349/month
• Wegovy 1.0mg: $1,349/month
• Wegovy 1.7mg: $1,349/month
• Wegovy 2.4mg (maintenance dose): $1,349/month

Novo Nordisk uses a flat pricing model — every dose costs the same monthly list price. This means you pay the same amount during the titration phase as you do on the full maintenance dose, which is frustrating for patients who are on lower doses for the first four months of treatment.

Self-Pay: The Novo Nordisk Savings Offer

In early 2026, Novo Nordisk launched a limited-time self-pay pricing program to compete with Eli Lilly's LillyDirect. Eligible patients without insurance coverage for Wegovy can access the medication for $199 per month.

Key details of this offer:

• Price: $199/month for all Wegovy injection doses
• Duration: Introductory offer valid through June 2026
• Eligibility: Patients without insurance coverage for Wegovy, or those whose insurance denies the claim
• How to access: Through NovoCare.com or participating telehealth providers
• Limitation: Cannot be combined with government insurance (Medicare, Medicaid, Tricare)

This represents an 85% discount from the list price and is Novo Nordisk's direct response to competitive pressure from Eli Lilly's Zepbound, which has been available at $349/month through LillyDirect since late 2024.

Oral Wegovy: The $149/Month Game-Changer

Oral Wegovy (semaglutide tablet, 50mg daily) launched in January 2026 and represents a paradigm shift in GLP-1 accessibility. For the first time, patients can access FDA-approved semaglutide for weight loss without injections.

Pricing for Oral Wegovy:

• Lowest dose (starting): $149/month self-pay
• Maintenance dose: Pricing varies; typically $149–$299/month depending on dose and pharmacy
• With commercial insurance: Copays as low as $25/month with the NovoCare Savings Card

The tablet must be taken daily on an empty stomach with no more than 4 ounces of water, at least 30 minutes before eating, drinking, or taking other medications. Clinical trials demonstrated approximately 15–17% body weight loss over 68 weeks — comparable to the injectable form.

Oral Wegovy is now the most affordable FDA-approved semaglutide option on the market, undercutting even compounded alternatives in price while carrying full regulatory approval and manufacturing quality controls.

Wegovy with Insurance

Insurance coverage for Wegovy has expanded significantly since its 2021 launch, but it remains inconsistent. Here is what to expect:

• Typical copay with commercial insurance: $25–$200/month
• With Novo Nordisk Savings Card + insurance: As low as $0 for 3 months, then $25–$50/month
• Prior authorization required: Nearly always — expect your doctor to document BMI of 30+ (or 27+ with a weight-related condition)
• Step therapy: Some insurers require trying cheaper alternatives first (e.g., phentermine, orlistat)

Coverage varies dramatically by employer and plan. Large employers in tech, finance, and healthcare are more likely to cover GLP-1 medications. Smaller employers and high-deductible health plans often exclude them.

Pro tip:If your insurance denies Wegovy, ask your doctor to submit a peer-to-peer review and an appeal letter citing the 2022 AAP clinical practice guidelines. Approval rates on appeal are approximately 40–60% for patients who meet clinical criteria.

Medicare Coverage Starting July 2026

A major milestone for GLP-1 accessibility: Medicare Part D will begin covering Wegovy and Zepbound for obesity starting July 2026 through a Bridge program negotiated by CMS. Here is what Medicare beneficiaries need to know:

• Estimated copay: $50/month for eligible beneficiaries
• Eligibility: BMI of 30 or above, or BMI 27+ with at least one weight-related condition
• Prior authorization: Required; must be submitted by treating physician
• Covered medications: Wegovy (injectable and oral), Zepbound
• Not covered: Ozempic prescribed off-label for weight loss

This is a historic change. Medicare had explicitly excluded weight loss medications since 2003. The new coverage is expected to benefit approximately 3.4 million Medicare beneficiaries who meet the clinical criteria for GLP-1 treatment.

For a complete breakdown, see our Medicare GLP-1 Coverage Guide.

Compounded Semaglutide Alternative

Compounded semaglutide has been available from compounding pharmacies and telehealth providers at prices ranging from $149–$499/month. However, the regulatory landscape has shifted dramatically:

• The FDA declared the semaglutide shortage officially over in late 2024
• Without an active shortage, 503A compounding pharmacies lose their legal basis to compound copies of brand-name drugs
• The FDA has issued warning letters to more than 50 compounders
• Several major telehealth platforms have stopped offering compounded semaglutide

Compounded semaglutide is not FDA-approved. It does not undergo the same manufacturing quality controls, potency testing, or sterility standards as brand-name Wegovy. The FDA has documented cases of contaminated and sub-potent compounded products.

With Oral Wegovy now available at $149/month, the cost argument for compounded semaglutide has largely evaporated. Read our compounded vs brand comparison for the full analysis.

NovoCare and Manufacturer Coupons

Novo Nordisk offers several programs to reduce the cost of Wegovy: